Zobrazeno 1 - 10
of 1 101
pro vyhledávání: ''
Autor:
Ming Li, Quan Li, Ni Liu, Frances A. Shepherd, Teklab Gebregiworgis, Ming-Sound Tsao, Nadeem Moghal, Nhu-An Pham, Mitsuhiko Ikura, Ningdi Feng Liu, Zhenhao Fang, Hirotsugu Notsuda, Ku-Geng Huo, Christopher B. Marshall
Publikováno v:
Journal of Thoracic Oncology. 17:277-288
Introduction Mutations in BRAF occur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not c
Autor:
Antti Mäkitie, Karin Blomgren, Markus Lilja, Ida Kotisalmi, Maija Hytönen, Sara Sainio, Marie Lundberg
Publikováno v:
Clinical Otolaryngology. 47:174-180
Publisher Copyright: © 2021 John Wiley & Sons Ltd Objectives Postoperative infection is the most common complication after septoplasty. Pre- or postoperative prophylactic antibiotics are commonly used, although no official guidelines exist. Design W
Autor:
Johanna Lilja, Ella-Maria Vesilahti, Johanna M. Anttila, Hussein Al-Akhrass, Johanna Ivaska, Emilia Peuhu, Pauliina Munne, Mika Pietilä, Juha Klefström, Heidi M. Haikala
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 16, Iss 1, Pp 116-129 (2022)
Molecular Oncology, Vol 16, Iss 1, Pp 116-129 (2022)
In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals due to therapy resistance. Identifying alternative HER2‐related therapeutic targets could off
Autor:
Julie A. Price Hiller, Nancy A. Nixon, Anil A. Joy, Bassam Basulaiman, John Hilton, Terry L. Ng, Mohammed F.K. Ibrahim, Dean Fergusson, Marta Sienkiewicz, Arif Awan, Brian Hutton, Mark Clemons, Lisa Vandermeer, John R. Mackey, Deanna Saunders, Xiaofu Zhu, Gregory R. Pond, Judith Meza-Junco, Lacey D. Pitre, Kednapa Thavorn
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 58, Iss, Pp 42-49 (2021)
Breast, Vol 58, Iss, Pp 42-49 (2021)
Background Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised
Autor:
Dirk Waldschmidt, J-B. Bachet, Lawrence Fong, J. Tabernero, Michele Reni, H-M. Chang, Sara Lonardi, G. Cole, Margaret A. Tempero, Andrew Eugene Hendifar, D-Y. Oh, L.C. Tsao, Teresa Macarulla, Danelle F. James, E. Van Cutsem, Juan Maurel, Lisa M. Coussens, Naureen Starling, Rocio Garcia-Carbonero
Publikováno v:
Scientia
Ibrutinib; Metastatic pancreatic adenocarcinoma; Phase III Ibrutinib; Adenocarcinoma de páncreas metastásico; Fase III Ibrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III First-line treatment of metastatic pancreatic ductal adenocarcinoma
Autor:
Karolina Pavic, Taru Varila, Eliisa Löyttyniemi, Claire M. Lucas, Jukka Westermarck, Eleonora Makela, Maija Itälä-Remes, Tea Ammunét, Veli-Matti Kähäri, Richard E. Clark, Venkata Kumari Bachanaboyina, Urpu Salmenniemi, Laura L. Elo, Srikar G. Nagelli
Publikováno v:
CLINICAL CANCER RESEARCH
Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2A splicing variant, novel CIP2
Autor:
José Manuel Mas, Carmen Montoto, Andrea Naves, Baldomero Oliva, Alonso Fernández-Nistal, Araceli López, Cristina Segú-Vergés, Enric Carcereny, Guillem Jorba, Mireia Coma
Publikováno v:
Oncotarget
Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyr
Autor:
Gerd Bendas, Abdullah Al Nahain, Martin Heyes, Vito Ferro, Lukas Maria Gockel, Jin-Ping Li, Honglian Li, Stefan Holdenrieder, Christian Gorzelanny, Martin Schlesinger
Publikováno v:
ACS Applied Materials & Interfaces. 13:7080-7093
Low-molecular-weight heparin (LMWH) is the guideline-based drug for antithrombotic treatment of cancer patients, while its direct antitumor effects are a matter of ongoing debate. Although therapeutically established for decades, LMWH has several dra
Publikováno v:
Laryngoscope Investigative Otolaryngology
Laryngoscope Investigative Otolaryngology, Vol 6, Iss 1, Pp 25-33 (2021)
Laryngoscope Investigative Otolaryngology, Vol 6, Iss 1, Pp 25-33 (2021)
Background Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and
Autor:
Michael Rink, Michael Moran, Stephan Bernhardt, Lothar Bergmann, M. Schmid, Katrin Schlack, Martin Boegemann, Marcus Hubbe, Arne Strauss
Publikováno v:
Future Oncology. 16:2939-2948
Aim: Examine the effects of baseline hypertension (HTN) and statin or proton pump inhibitor (PPI) use on sunitinib treatment outcomes in STAR-TOR, a real-world registry. Materials & methods: Presence or absence of HTN and use or nonuse of statins or